Digoxin inhibits PDGF-BB-induced VSMC proliferation and migration through an increase in ILK signaling and attenuates neointima formation following carotid injury

GAOLIANG YAN¹, QINGJIE WANG¹, SHENGDA HU¹, DONG WANG¹, YONG QIAO¹, GENSHAN MA¹, CHENGCHUN TANG¹ and YUCHUN GU²

¹Department of Cardiology, Zhongda Hospital of Southeast University Medical School, Nanjing, Jiangsu 210009; ²Institute of Molecular Medicine (IMM), Peking University, Beijing 100190, P.R. China

Received November 27, 2014; Accepted July 31, 2015

DOI: 10.3892/ijmm.2015.2320

Abstract. The increased proliferation and migration of vascular smooth muscle cells (VSMCs) are key events in the development of artery restenosis following percutaneous coronary intervention. Digoxin has long been used in the treatment of heart failure and has been shown to inhibit the proliferation of cancer cells through multiple pathways. However, the potential role of digoxin in the regulation of VSMC proliferation and migration and its effectiveness in the treatment of cardiovascular diseases, such as restenosis, remains unexplored. In the present study, we demonstrate that digoxin-induced growth inhibition is associated with the downregulation of CDK activation and the restoration of p27Kip1 levels in platelet-derived growth factor (PDGF)-stimulated VSMCs. In addition, we found that digoxin restored the PDGF-BB-induced inhibition of integrin linked kinase (ILK) expression and prevented the PDGF-BB-induced activation of glycogen synthase kinase (GSK)-3β. Furthermore, digoxin inhibited adhesion molecule and extracellular matrix relative protein expression. Finally, we found that digoxin significantly inhibited neointima formation, accompanied by a decrease in cell proliferation following vascular injury in rats. These effects of digoxin were shown to be mediated, at least in part, through an increase in ILK/Akt signaling and a decrease in GSK-3β signaling in PDGF-BB-stimulated VSMCs. In conclusion, our data demonstrate that digoxin exerts an inhibitory effect on the PDGF-BB-induced proliferation, migration and phenotypic modulation of VSMCs, and prevents neointima formation in rats. These observations indicate the potential therapeutic application of digoxin in the treatment of cardiovascular diseases, such as restenosis.

Introduction

During the switching from a differentiated/contractile to a dedifferentiated/synthetic phenotype, the increased proliferation and migration of vascular smooth muscle cells (VSMCs) are key events in the development of artery restenosis following percutaneous coronary intervention (1-3). All these events may be induced by cytokines, such as platelet-derived growth factor BB (PDGF-BB) (4). PDGF-BB initiates a multitude of biological effects through the activation of intracellular signal transduction pathways that contribute to VSMC phenotypic modulation, proliferation, migration and collagen synthesis. The importance of PDGF-BB in the development of neointima formation has been established in models of arterial injury (5). Therefore, the inhibition of PDGF-stimulated VSMC proliferation, migration and phenotypic modulation may represent an important point of therapeutic intervention in restenosis following angioplasty.

Digoxin has been used as an effective therapy to treat patients with congestive heart failure (CHF) for decades (6,7). Previous studies have highlighted a new aspect of the biology of cardiac glycosides as versatile signal transducers (8,9) in that they control the transcription of specific genes (10). Cardiac glycosides (endogenous and exogenous) have been implicated in the regulation of a number of important physiological and pathological states (11-13). Furthermore, unexpected results from epidemiological studies describing significantly lower mortality rates of patients with cancer receiving cardiac glycosides have sparked new interest into the anticancer properties of these drugs. Subsequent in vitro and in vivo studies verified these initial observations (14-16). Another study demonstrated that digoxin inhibited the growth of neuroblastoma tumor xenografts in mice and angiogenesis in chick chorioallantoic membrane assays (17). In addition, in a previous study, Yoshida et al (18) demonstrated that digoxin suppressed
retinal and choroidal neovascularization, which blocks several proangiogenic pathways. However, the role of digoxin in regulating VSMC activation is not yet clearly understood. Although digoxin has been found to attenuate the development of right ventricle hypertrophy and prevent pulmonary vascular remodeling, as well as the increase in pulmonary artery smooth muscle cell [Ca2+]i and pH levels that occur in mice exposed to chronic hypoxia (19), little is known about the role of digoxin in regulating aortic VSMC proliferation and migration and its effectiveness in the prevention of restenosis.

In this study, we demonstrate that digoxin exerts an inhibitory effect on the PDGF-BB-induced proliferation, migration and phenotypic modulation of VSMCs, and prevents neointima formation induced by balloon injury. We also demonstrate that the digoxin-induced growth inhibition is associated with the downregulation of CDK activation and the restoration of p27Kip1 levels in PDGF-stimulated VSMCs. This effect of digoxin is mediated, at least in part, through an increase in integrin linked kinase (ILK)/Akt signaling and a decrease in glycerol synthase kinase (GSK)-3β signaling in PDGF-BB-stimulated VSMCs.

Materials and methods

Ethics statement. Animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (DHWE publication no. 96-01, revised in 2002) and was approved by the Ethics Review Board for Animal Studies of Institute of Southeast University, Nanjing, China.

Reagents. Recombinant human PDGF-BB, trypan blue reagent, the phosphoinositide 3-kinase (PI3K) specific inhibitor, LY294002, the GSK-3β antagonist, SB415286, and cell proliferation reagent 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma, St. Louis, MO, USA. The proliferating cell nuclear antigen (PCNA) antibody was purchased from Cell Signaling Technology (Product no. 2586s). Trypsin-ethylenediaminetetraacetic acid (EDTA) (0.25%), Dulbecco's modified Eagle medium/F12 (DMEM/F12) and fetal bovine serum (FBS) were from PromoCell (Heidelberg, Germany). The digoxin injection was acquired from Minsheng Pharmaceutical Group Co., Ltd. (Hangzhou, China). The membranes were blocked, and then incubated with various antibodies overnight, such as anti-CDK4 (Cat. no. SC23896, 1:500), anti-CDK6 (Cat. no. SC53638, 1:500), anti-p27Kip1 (Cat. no. SC1641, 1:500) (all from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-SM22a (Cat. no. A5228, 1:1,000), anti-calponin (Cat. no. C2687, 1:1,000), anti-smooth muscle (SM) α-actin (Cat. no. A2172, 1:1,000) (all from Sigma), anti-phospho-Jun NH2-terminal kinase (p-JNK; Tyr183/185; Cat. no. 5135, 1:1,000), anti-JNK (Cat. no. 9258 1:1,000), anti-p38 mitogen-activated protein kinase (MAPK; Cat. no. 9228, 1:1,000), anti-phospho-p38 MAPK (Thr180/Tyr182; Cat. no. 4092, 1:1,000; p-MAPK), anti-extracellular signal-regulated kinase (ERK)1/2 (Cat. no. 4696, 1:1,000), anti-phospho-ERK1/2 (p-ERK, Tyr204; Cat. no. 4374, 1:1,000), anti-phospho-Akt (p-Akt, S473; Cat. no. 4686, 1:1,000), anti-phospho-GSK-3β (Cat. no. 9832, 1:1,000), anti-phospho-pS9; Cat. no. 14630, 1:1,000), anti-phospho-GSK-3β (p-GSK-3β, S9; Cat. no. 14630, 1:1,000), anti-phospho-GSK-3β (Cat. no. 9832, 1:1,000) (all from Cell Signaling Technology), anti-ILK (Cat. no. 6183, 1:1,000), BD Biosciences, Franklin Lakes, NJ, USA), anti-intercellular adhesion molecule-1 (ICAM-1; Cat. no. 4915, 1:500), anti-vascular cell adhesion molecule-1 (VCAM-1; Cat. no. 13662, 1:500) (both from Cell Signaling Technology), anti-matrix metalloproteinase (MMP)-2 (Cat. no. SC13594, 1:500), anti-MMP-9 (Cat. no. SC21733, 1:500) anti-tissue inhibitors of metalloproteinase (TIMP)-1 (Cat. no. SC21734, 1:500), anti-TIMP-2 (Cat. no. SC365671, 1:500) (all from Santa Cruz Biotechnology, Inc.), anti-glycerol-aldehyde 3-phosphate dehydrogenase (GAPDH; Cat. no. 5174,
ligated, and the blood flow was restored. Following balloon external carotid artery and inflated to 2.0-3.0 atm and with into the common carotid artery through an arteriotomy in the (Edwards Lifesciences, Irvine, CA, USA) was introduced as previously described (20). Sprague-Dawley rats (n=48, Balloon injury and morphometric analysis of neointima under a fluorescence microscope (Nikon, Tokyo, Japan). Dark. Cells were mounted with 90% glycerol-PBS and examined bathed with FITC-conjugated secondary antibodies for 1 h in the for 1 h at room temperature, washed with PBS, and then incu 30 min. The cells were then incubated with primary antibodies were blocked with 2% bovine serum albumin (BSA) in PBS for 0.1% Triton X-100 in PBS for 5 min. After washing, the cells were washed with PBS, fixed with 3.7% paraformaldehyde and stained with 0.1% crystal violet/20% methanol and counted. The migrated cell numbers were calculated as the number of migrated cells/5 different random high-power fields (at x200 magnification).

Migration assay. Migration assay was performed using the Transwell system (a 6.5-mm polycarbonate membrane with 8.0-μm pores; Corning, Inc., Corning, NY, USA) (20). Cells suspensions (5x10⁴), containing fresh serum-free medium, were seeded upper chamber. PDGF-BB with or without digoxin was added to the bottom chamber as the chemoattrac tant. The cells were allowed to migrate through the membrane to the lower surface for 6 h. Cells on the upper surface of the membrane that had not migrated were scraped off with cotton swabs, and cells that had migrated to the lower surface were fixed by 3.7% paraformaldehyde and stained with 0.1% crystal violet/20% methanol and counted. The migrated cell numbers were calculated as the number of migrated cells/5 different random high-power fields (at x200 magnification).

Immunofluorescence staining. Following treatment, the cells were washed with PBS, fixed with 3.7% paraformaldehyde for 15 min at room temperature, and then treated with 0.1% Triton X-100 in PBS for 5 min. After washing, the cells were blocked with 2% bovine serum albumin (BSA) in PBS for 30 min. The cells were then incubated with primary antibodies for 1 h at room temperature, washed with PBS, and then incubated with FITC-conjugated secondary antibodies for 1 h in the dark. Cells were mounted with 90% glycerol-PBS and examined under a fluorescence microscope (Nikon, Tokyo, Japan).

Balloon injury and morphometric analysis of neointima formation. Balloon denudation of the left common carotid artery of the male Sprague-Dawley rats was performed, as previously described (20). Sprague-Dawley rats (n=48, weighing 300-350 g) were anesthetized using chloral hydrate (350 mg/kg, i.p.), and the left common and external carotid arteries were exposed and isolated. A 1.5 F Fogarty catheter (Edwards Lifesciences, Irvine, CA, USA) was introduced into the common carotid artery through an arteriotomy in the external carotid artery and inflated to 2.0-3.0 atm and withdrawn repeatedly 3 times. The external carotid artery was then ligated, and the blood flow was restored. Following balloon injury, digoxin (1.0 mg/kg/day) was intraperitoneal injected for 14 days. The control rats also received a similar volume of distilled water. For preparing the sham-operated rats, the left common carotid artery and external carotid artery were exposed and ligated as above, but the catheter was not inserted into the vessels. The arteries were collected on day 14 after balloon injury, and embedded in paraffin to prepare cross sections. Sections for analysis were taken from the middle part of the injured segment and cut at equally spaced intervals of 2 mm. The prepared sections were cleared with xylene, and hydrated with ethanol. The sections were stained with hematoxylin and eosin or incubated overnight at 4˚C with primary antibodies (PCNA: 1:200). The incubated sections were treated with biotinylated pan-specific antibody (Vector Laboratories, Burlingame, CA, USA) for 1 h and incubated in ABC solution (Elite ABC kit, Vector Laboratories) prepared according to the manufacturer's instructions. After 1 h of incubation, the sections were stained with diaminobenzidine (DAB) reagent (Vector Laboratories) and with methyl green counterstain. The stained sections were observed with a BX51 light microscope (Olympus, Tokyo, Japan). Neointima thickening was assessed using the intima/media (I/M) thickness ratio measured from haematoxylin and eosin-stained arterial cross sections with a computer-based Image-Pro Morphometric System in a double-blind manner. Four discontinuous sections from each vessel were measured in a Sprague-Dawley rat, whereas 6 rats were used in each experimental group [the control (distilled water, the sham-operated rats and the digoxin-treated rats].

Statistical analysis. Data are presented as the means ± SEM. ANOVA and a paired or unpaired t-test were performed for statistical analysis where appropriate. A value of P<0.05 was considered to indicate a statistically significant difference.

Results

Digoxin inhibits the proliferation of VSMCs induced by PDGF-BB. The VSMCs were pre-treated with various concentrations (10-500 nmol/l) of digoxin followed by stimulation with PDGF-BB (25 μg/l) for 24 h. Digoxin inhibited the PDGF-BB-induced proliferation of VSMCs in a concentration-dependent manner (Fig. 1A and B). The number of cells was significantly increased following treatment with 25 μg/l PDGF-BB compared to the non-stimulated group. However, the cell numbers were significantly reduced following co-culture with 10-500 nM digoxin. In addition, MTT assay revealed the same inhibitory pattern on VSMC proliferation (Fig. 1B). The cells treated with digoxin (10-500 nM) for 24 h in the absence of PDGF-BB showed no significant difference in viability compared with the untreated cells, suggesting that digoxin is not cytotoxic at the concentrations tested. Furthermore, re-endothelialization is a vital process for arterial injury repair. To exclude a cell cytotoxic effect of digoxin, we determined cell necrosis by trypan blue exclusion in the absence or presence of digoxin. We examined the effects of digoxin on endothelial cell viability. The HUVECs were incubated in the absence or presence of digoxin for 48 h before their viability was analyzed according to their ability to exclude trypan blue. Digoxin did not induce the necrosis of HUVECs at up to 48 h (Fig. 1C), and digoxin had no negative effect on VSMC viability (Fig. 1D).
Digoxin inhibits the PDGF-BB-induced cell cycle progression of VSMCs. To elucidate the mechanisms responsible for the anti-proliferative effects of digoxin, the effects of digoxin on cell cycle progression were analyzed. The cells were pre-incubated in the presence or absence of digoxin in serum-free medium for 24 h and then stimulated with PDGF-BB (25 µg/l). After 24 h, an individual nuclear DNA content is reflected as the fluorescence intensity of incorporated PI. As shown by flow cytometry, treatment with PDGF-BB alone significantly increased the percentage of cells in the S phase while decreasing the G0/G1 cell population. By contrast, digoxin at a concentration of 100 nM significantly increased the fraction of G0/G1 phase cells and decreased the number of VSMCs in the S phase, indicating that digoxin prevented cell cycle entry/progression into the G0/G1 phase (Fig. 2). This result suggests that digoxin acts at the early stages of cell cycle progression.

Effects of digoxin on the PDGF-BB-induced expression of cell cycle-related proteins in VSMCs. Cell cycle progression is tightly regulated through specific CDK cyclin protein complexes (21). To elucidate the mechanisms responsible for digoxin-induced cell cycle arrest, the effects of digoxin on cell cycle events, such as CDK protein expression, were analyzed by western blot analysis. The expression of CDK4 and CDK6 was induced by PDGF-BB (25 µg/l), whereas treatment with digoxin (100 nM) significantly decreased the expression of these molecules (Fig. 3A). Cyclin-CDK complexes are precisely regulated by cell cycle inhibitors that block their catalytic activity. One such inhibitor is p27Kip1, which inactivates the cyclin-CDK complexes in the G1 phase, leading to cell cycle arrest (22). Subsequently, we assessed the effects of digoxin on the induction of p27Kip1 expression. p27Kip1 was constitutively expressed in the serum-starved quiescent VSMCs and was downregulated by stimulation with PDGF-BB. By contrast, pre-treatment with digoxin partly restored p27Kip1 expression to levels that were comparable to those in the quiescent cells (Fig. 3).

Digoxin inhibits the activation of the GSK-3β/Akt signaling cascade induced by PDGF-BB in VSMCs. To further delineate the cellular and molecular mechanisms underlying the inhibition of PDGF-BB-induced VSMC growth by digoxin,
the serum-starved VSMCs were stimulated with PDGF-BB for various periods of time in the absence or presence of digoxin (100 nM), and the phosphorylation status of ERK1/2, JNK and p38 MAPK, was measured by western blot analysis using antibodies that identify the active (phosphorylated) forms of these kinases. Our results revealed that PDGF-BB induced the rapid and sustained phosphorylation of ERK1/2, JNK and p38, without affecting their total levels. However, no changes were observed in the phosphorylated forms of ERK1/2, JNK and p38 when the cells were pre-treated with digoxin at the...
indicated time points (Fig. 5A and B). Previous studies have also demonstrated that the GSK3β/Akt signal transduction pathway is critically involved in VSMC proliferation and migration. Therefore, we evaluated the effects of digoxin on the PDGF-induced activation of the GSK3β/Akt pathway. Our results revealed that PDGF-BB induced the rapid and sustained phosphorylation of GSK3β and Akt (Fig. 5A, C and D). However, the PDGF-BB-induced GSK3β phosphorylation was significantly impaired by digoxin in a time-dependent manner. However, the increased phosphorylation of Akt was even observed at 15 min after PDGF-BB and digoxin co-treatment, and was sustained for up to 30 min compared to stimulation with PDGF-BB alone as assessed by western blot analysis. These results suggest that digoxin reduces GSK-3β and increases Akt activity in PDGF-BB-stimulated VSMCs.

Digoxin activates the ILK signaling cascade and inhibits the activation of the GSK-3β signaling cascade induced by PDGF-BB in VSMCs. ILK has been shown to be a critical effector in the PI3K-dependent signaling pathway that is downstream from both growth factor and integrin receptor activation (23). The stimulation of ILK results in the activation of Akt and the inhibition of GSK-3β (23). Thus, we further examined the effects of digoxin on the PDGF-BB-induced activation of the PI3K/ILK/GSK-3β signal transduction pathway in VSMCs. The VSMCs were pre-cultured in serum-free medium for 24 h and then stimulated with PDGF-BB for 48 h in the absence or presence of digoxin (100 nM). The protein levels of ILK, GSK-3β and Akt were determined by western blot analysis. Our results revealed that digoxin restored the expression of ILK which was suppressed by PDGF-BB and prevented the PDGF-BB-induced increase in GSK-3β expression without affecting the level of Akt in the cells treated with both PDGF-BB and digoxin (Fig. 6).

Digoxin inhibits PDGF-BB-induced cell migration through the PI3K/GSK-3β signaling cascade. The migration of smooth muscle cells from the media to the intimal region is another important component of vascular lesion formation (24). PDGF-BB initiates a multitude of biological effects through the activation of intracellular signal transduction pathways that contribute to VSMC migration (25). Thus, we examined the effects of digoxin on PDGF-BB-induced VSMC migration by Transwell assay which is used to assess chemotaxis. We examined whether digoxin plays a role in regulating VSMC migration. Treatment with PDGF-BB (25 µg/l) for 6 h increased the basal migration of the VSMCs by >2-fold (Fig. 7); however, compared to stimulation with PDGF-BB alone, a 30% decrease in cell migration was observed in the cells treated with both PDGF-BB and digoxin. These results suggest that digoxin is a potent inhibitor of VSMC migration. Co-stimulation with LY294002, an inhibitor of PI3K, inactivated ILK/Akt and prevented the anti-migratory effects of digoxin in the VSMCs. However, pre-treatment with SB415286, a specific antagonist of GSK-3β, resulted in a >2-fold decrease in the number of VSMCs moving across the membrane, compared to co-culture
with PDGF-BB and digoxin. These data demonstrate that digoxin inhibits PDGF-BB-induced cell migration through the PI3K/GSK-3β signaling cascade.

**Digoxin inhibits the PDGF-BB induced expression of adhesion molecules and effects the expression of key proteins in the extracellular matrix (ECM) in VSMCs.** To elucidate the molecular mechanisms responsible for the inhibitory effects of digoxin on VSMC migration, we examined the effects of digoxin on the migration regulatory proteins, ICAM-1 and VCAM-1. The stimulation of serum-starved VSMCs with PDGF-BB for 48 h in the absence of digoxin induced the upregulation of ICAM-1 and VCAM-1 protein expression (Fig. 8A and B). Treatment with 100 nM digoxin resulted in an ~60% decrease in the protein levels of ICAM-1 compared to the levels in the PDGF-BB-treated cells, and a 40% decrease was observed in the VCAM-1 level.

It is well known that MMPs degrade the ECM and promote VSMC migration from the media to the intimal region. The balance of MMPs and TIMPs is crucial to maintaining the dynamic equilibrium of the ECM (26). Therefore, we detected key factors in the ECM in VSMCs. Digoxin increased the protein expression of TIMP-1 and TIMP-2 which was suppressed by PDGF-BB in vitro (Fig. 8C). A similar result was obtained for the ratio of TIMP-2/MMP-2 and TIMP-1/MMP-9 (Fig. 8D). These findings suggest that digoxin inhibits the migration of VSMCs induced by PDGF-BB by suppressing the expression of migration-related proteins in these cells.

**Effects of digoxin on neointima formation and cell proliferation in vivo.** To investigate the role of digoxin in regulating VSMC proliferation in vivo, rat carotid arteries were harvested on day 14 following balloon injury, and an increased I/M thickness ratio of the carotid arteries was observed (Fig. 9A). The administration of digoxin injection (1.0 mg/kg/day) significantly decreased the I/M thickness ratio by >45% compared with the injured control rats (Fig. 9B) and inhibited the injury-induced increase in PCNA expression in the neointima of carotid arteries (Fig. 9C), and attenuated neointima formation. These results suggest that digoxin exerts an inhibitory effect on cell proliferation in vivo, and may be an effective agent for the prevention of restenosis following angioplasty.

**Discussion**

In the present study, to the best of our knowledge, we demonstrate for the first time that digoxin inhibits the PDGF-BB-induced phenotypic switching, proliferation and migration of VSMCs, and prevents neointima formation induced by balloon injury, at least in part through an increase in ILK/Akt signaling and a decrease in GSK-3β signaling.

Indeed, a number of studies have described the effects of cardiac glycosides, such as digoxin and digitoxin, on the regulation of cell attachment (27), the orientation of polarity (28), protein trafficking (29) and the induction of proliferation (30,31). Overall, it is now clear that the ultimate response to cardiac glycoside treatment is dependent on the tissue, exposure time and dose (15). Numerous studies have confirmed the anti-proliferative effects of cardiac glycosides in several cancer cell lines, including breast (32), prostate (33), melanoma (34), pancreatic (35), lung (36), leukaemia (37), neuroblastoma (38) and renal adenocarcinoma (39). The exact mechanisms underlying these effects of cardiac glycosides are not yet fully understood. Our study demonstrated that the anti-
proliferative activity of digoxin was associated with cell cycle arrest in the G0/G1 phase (Fig. 2). Cell cycle progression is a tightly regulated process that involves a complex cascade of events. A previous study indicated that pharmacological interventions to regulate the cell cycle inhibit VSMC proliferation and block neointimal hyperplasia (40). Therefore, the inhibition of VSMC cycle progression is considered an effective strategy for the control of VSMC proliferation. In this study, the fact that digoxin permitted the VSMCs to arrest in the G0/G1 phase suggests that the modulation of cell cycle regulatory proteins occurs following digoxin treatment. CDK4 and CDK6 are key mediators during the progression from the G0/G1 to the S phase of the cell cycle by forming complexes with cyclin A, E and D1 (41). Our data demonstrated that the expression of the cell cycle regulatory proteins, CDK4 and CDK6, decreased after the VSMCs were treated with digoxin, compared to stimulation with PDGF-BB alone (Fig. 3), indicating that cell cycle arrest in the G0/G1 phase is due to the downregulation of CDK/cyclin complex expression (4). The results from different research groups have also demonstrated that p27Kip1 inhibits the proliferation and migration of VSMCs (42,43). In the present study, the digoxin-induced upregulation of p27Kip1 expression was consistent with the inhibitory effects of digoxin on VSMC migration. These results suggest that the effects of digoxin on p27Kip1 expression are involved in its inhibitory effects on VSMC proliferation and migration.

VSMCs can undergo transition from a quiescent, contractile/differentiated phenotype to a synthetic/dedifferentiated phenotype (44). To date, compelling evidence has indicated that PDGF-BB induces a profound suppression of VSMC marker
gene expression through multiple complementary pathways and plays a pivotal role during restenosis (20,45). In accordance with previous studies, we observed that PDGF-BB decreased SMα-actin, SM22a and calponin expression. Our in vitro
experiments revealed that treatment with digoxin partly restored the expression of SM α-actin, SM22a and calponin (Fig. 4), accompanied by a decrease in cell proliferation and migration. These results suggest that digoxin halts the change toward a deleterious VSMC phenotype induced by PDGF-BB, which in turn contributes to the suppression of neointima formation.

The mechanisms through which digoxin inhibits PDGF-BB-induced VSMC proliferation, migration and phenotypic modulation remain largely unclear. ILK is a widely expressed and evolutionally conserved component of cell-ECM adhesions. Activated ILK can directly phosphorylate Akt and GSK-3β (46); the phosphorylation of GSK-3β results in the inhibition of ILK. Yudowski et al (47) found that PI3K-Akt activation was an important part of the complex and was bound to a proline-rich region of the catalytic α-subunit of Na+/K+-ATPase. In a similar manner, ouabain mediates proliferation through the nitric oxide-induced production of reactive oxygen species through the activation of the PI3K cascade (48). Our data demonstrated that digoxin restored the PDGF-BB induced inhibition of ILK expression and prevented the PDGF-BB-induced activation of GSK-3β without affecting the activation of the ERK1/2, p38 and JNK and p38 MAPK cascade. Additionally, digoxin prevented the PDGF-BB induced proliferation and migration of VSMCs accompanied by the activation of Akt. These findings are consistent with those of a previous study showing that digoxin prevents TNF-α-induced apoptosis of endothelial cells accompanied by the activation of Akt through PI3K signaling (49).

It has previously been demonstrated that MMPs are rapidly activated following vascular injury in both atherosclerosis and angioplasty (50). MMPs degrade the ECM and promote VSMC migration from the media to the intimal region, and then initial VSMCs undergo proliferation, while migrating VSMCs secrete vast ECM products, including collagen I and III, progressively resulting in neointima formation (51). In this study, we found that digoxin significantly inhibited the expression of MMP-2 and MMP-9 induced by PDGF stimulation, and also had a significant effect on both TIMP-2 and TIMP-1 (the inhibitors of the MMPs). The ratios of MMP-2/TIMP-2 and MMP-9/TIMP-1 imply that VSMC migration may be a disequilibrium process induced by PDGF-BB, and digoxin was able to balance the ratio to a normal condition. Therefore, the regulatory effects of digoxin on MMPs and TIMPs which are key factors in the ECM for VSMC migration, may contribute to its anti-migratory effect on VSMCs.

In the present study, to determine whether our in vitro findings have any physiological relevance, we evaluated the effects of digoxin on neointima formation using an animal model of arterial balloon-injury. Although the doses of digoxin injection (1.0 mg/kg/day) administered in this study are higher than those administered to humans, the comparison of the dosages between species is complicated by a number of factors. For example, on the basis of body weight versus surface area between species is complicated by a number of factors. For

References
1. Davis-Dusenbery BN, Wu C, Hata A and Sessa WC: Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol 21: 2370-2377, 2011.
2. Goel SA, Guo LW, Liu B and Kent KC: Mechanisms of post-intervention arterial remodelling. Cardiovasc Res 96: 363-371, 2012.
3. Wentzraub WS: The pathophysiology and burden of restenosis. Am J Cardiol 100: 3K-9K, 2007.
4. Dzau VJ, Braun-Dullaeus RC and Sedding DG: Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med 8: 1249-1256, 2002.
5. Raines EW: PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15: 237-254, 2004.
6. Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE and Braunwald E: Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: A propensity-matched study of the DIG trial. Int J Cardiol 123: 138-146, 2008.
7. Pervaiz MH, Dickinson MG and Yamani M: Is digoxin a drug of the past? Cleve Clin J Med 73: 821-824, 826, 829-832, 2006.
8. Newman RA, Yang P, Pawlus AD and Block KJ: Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8: 36-49, 2008.
9. Prassas I and Diamandis EP: Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov 7: 926-935, 2008.
10. Takara K, Takagi K, Tsujimoto M, Ohnishi N and Yokoyama T: Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun 306: 116-120, 2003.
11. Schoner W: Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem 269: 2440-2448, 2002.
12. Schoner W and Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides and their mechanisms of action. Am J Cardiovasc Drugs 7: 173-189, 2007.
13. Schoner W and Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides: Their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 293: C509-C536, 2007.
14. López-Lázaro M: Digitoxin as an anticancer agent with selectivity for cancer cells: Possible mechanisms involved. Expert Opin Ther Targets 11: 1043-1053, 2007.
15. Mijatovic T, Van Quaquebeke E, Delest B, Debeir O, Darro F and Kiss R: Cardiostatic steroids on the road to anti-cancer therapy. Biochim Biophys Acta 1776: 32-57, 2007.
16. Winnicka K, Bielawska K and Bielaw ska A: Cardiac glycosides in cancer research and cancer therapy. Acta Pol Pharm 63: 109-115, 2006.
17. Svensson A, Azarbayjani F, Bäckum U, Matsumoto T and Christofferson R: Digoxin inhibits neuroblastoma tumor growth in mice. Anticancer Res 25 (1A): 207-212, 2005.
18. Yoshida T, Zhang H, Iwase T, Shon J, Semenza GL and Camacho PA: Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J 24: 1759-1767, 2010.
19. Abud EM, Maylor J, Undem C, Punjabi A, Zaiman AL, Myers AC, Sylvester JT, Semenza GL and Shimoda LA: Digoxin inhibits development of hypertrophic pulmonary hypertension in mice. Proc Natl Acad Sci USA 109: 1239-1244, 2012.
20. Wang L, Zheng J, Du Y, Huang Y, Li J, Liu B, Liu C, Zhu Y, Gao Y, Xu Q, et al: Cartilage oligomeric matrix protein maintains the contractile phenotype of vascular smooth muscle cells by interacting with alphal(/beta)1 integrin. Circ Res 106: 514-525, 2010.
21. Norbury C and Nurse P: Animal cell cycles and their control. Annu Rev Biochem 53: 36-49, 1984.
22. Malumbres M and Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231, 2001.
